海创药业：公司产品氘恩扎鲁胺参加了医保谈判

Core Viewpoint - The company, Haichuang Pharmaceutical, has participated in the medical insurance negotiation for its product, Deutetrabenazine, which has passed the review for inclusion in the National Basic Medical Insurance Drug List by 2025 [1] Group 1 - The company confirmed its participation in the medical insurance negotiation process [1] - The outcome of the negotiation will be announced by the National Healthcare Security Administration [1]